The Latest in Critical Care, 7/10/23 (Issue #8)
In The News
FDA approved the new intravenous antibiotic sulbactam-durlobactam (Xacduro) for healthcare-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex (A. baumannii). Sulbactam is a beta-lactam and durlobactam a beta-lactamase inhibitor. Carbapenem-resistant Acinetobacter infections increased by almost 80% between 2019 and 20…
Keep reading with a 7-day free trial
Subscribe to PulmCCM to keep reading this post and get 7 days of free access to the full post archives.